Production (Stage)
Hemostemix Inc.
HMTXF
$0.0836
-$0.0081-8.83%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 5.39% | 238.78% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.39% | 238.78% | |||
| Operating Income | -5.39% | -238.78% | |||
| Income Before Tax | 4.13% | -304.90% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 4.13% | -304.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 4.13% | -304.90% | |||
| EBIT | -5.39% | -238.78% | |||
| EBITDA | -5.39% | -238.78% | |||
| EPS Basic | -18.99% | -203.85% | |||
| Normalized Basic EPS | -25.53% | -176.47% | |||
| EPS Diluted | -18.99% | -203.85% | |||
| Normalized Diluted EPS | -25.53% | -176.47% | |||
| Average Basic Shares Outstanding | -20.03% | 36.44% | |||
| Average Diluted Shares Outstanding | -20.03% | 36.44% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||